Yesterday's Supreme Court ruling declaring that isolated genomic DNA is not eligible for patent protection, but that cDNA – “cloned” or “complementary DNA” – can be patented ignited a frenzy of news stories and commentaries about the decision. In a segment on KQED’s Forum this morning, Mildred Cho, PhD, associate director of the Stanford Center for Biomedical Ethics and a professor of pediatrics, joined the discussion on how the ruling will affect medical and science research. Listen to the full discussion here.
Previously: A closer look at Supreme Court’s decision on gene patenting and Supreme Court rules on Myriad’s “gene patenting” case
